These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34459434)

  • 1. Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review.
    Kumar R; Nuñez NA; Prokop LJ; Veldic M; Betcher H; Singh B
    J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):681-686. PubMed ID: 34459434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review.
    Kumar R; Garzon J; Yuruk D; Hassett LC; Saliba M; Ozger C; Oztosun C; Ahern K; Athreya AP; Singh B; Croarkin PE; Vande Voort JL
    Acta Psychiatr Scand; 2023 Mar; 147(3):248-256. PubMed ID: 36086813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Lamotrigine in Borderline Personality Disorder: A Systematic Review and Meta-Analysis.
    Pahwa M; Nuñez NA; Joseph B; Seshadri A; Gerberi DJ; Frye MA; Singh B
    Psychopharmacol Bull; 2020 Sep; 50(4):118-136. PubMed ID: 33012875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial.
    Ketter TA; Greist JH; Graham JA; Roberts JN; Thompson TR; Nanry KP
    J Clin Psychiatry; 2006 Mar; 67(3):400-6. PubMed ID: 16649826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression.
    McElroy SL; Zarate CA; Cookson J; Suppes T; Huffman RF; Greene P; Ascher J
    J Clin Psychiatry; 2004 Feb; 65(2):204-10. PubMed ID: 15003074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management.
    Calabrese JR; Sullivan JR; Bowden CL; Suppes T; Goldberg JF; Sachs GS; Shelton MD; Goodwin FK; Frye MA; Kusumakar V
    J Clin Psychiatry; 2002 Nov; 63(11):1012-9. PubMed ID: 12444815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.
    Pan PY; Lee MS; Lo MC; Yang EL; Yeh CB
    BMC Psychiatry; 2014 May; 14():145. PubMed ID: 24885966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder.
    Pinto OC; Akiskal HS
    J Affect Disord; 1998 Dec; 51(3):333-43. PubMed ID: 10333987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lamotrigine update and its use in mood disorders.
    Hurley SC
    Ann Pharmacother; 2002 May; 36(5):860-73. PubMed ID: 11978166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: A systematic review.
    van den Ameele S; van Diermen L; Staels W; Coppens V; Dumont G; Sabbe B; Morrens M
    J Affect Disord; 2016 Oct; 203():364-373. PubMed ID: 27344047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on lamotrigine in bipolar disorder.
    Goldsmith DR; Wagstaff AJ; Ibbotson T; Perry CM
    CNS Drugs; 2004; 18(1):63-7. PubMed ID: 14731061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine: a review of its use in bipolar disorder.
    Goldsmith DR; Wagstaff AJ; Ibbotson T; Perry CM
    Drugs; 2003; 63(19):2029-50. PubMed ID: 12962521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.
    Soares-Weiser K; Bravo Vergel Y; Beynon S; Dunn G; Barbieri M; Duffy S; Geddes J; Gilbody S; Palmer S; Woolacott N
    Health Technol Assess; 2007 Oct; 11(39):iii-iv, ix-206. PubMed ID: 17903393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained remission with lamotrigine augmentation or monotherapy in female resistant depressives with mixed cyclothymic-dysthymic temperament.
    Manning JS; Haykal RF; Connor PD; Cunningham PD; Jackson WC; Long S
    J Affect Disord; 2005 Feb; 84(2-3):259-66. PubMed ID: 15708424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.